Literature DB >> 1967720

Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction.

K J Hogg1, J D Gemmill, J M Burns, W K Lifson, A P Rae, F G Dunn, W S Hillis.   

Abstract

128 patients with acute myocardial infarction of duration 6 h or less were randomised in double-blind fashion to receive 30 U anistreplase over 5 min or 1.5 MU streptokinase over 1 h, both intravenously. Angiographic patency was assessed 90 min and 24 h from the start of therapy. 55% of patients who received anistreplase and 53% of patients who received streptokinase had patent infarct-related arteries (TIMI grade 2-3) at 90 min (95% CI 42-68% and 40-66%, respectively). At 24 h 81% and 87.5% of arteries were patent respectively (95% CI, 71-91% and 83.5-91.5%). Time to therapy had no significant effect on patency rates. There was one early reocclusion within 24 h in each treatment group and clinical evidence of reocclusion was recorded between 24 h and hospital discharge in a further 5 patients (streptokinase 3, anistreplase 2). With these regimens, therefore, anistreplase and streptokinase gave the same patency rates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967720     DOI: 10.1016/0140-6736(90)90069-h

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Thrombolytic therapy for acute myocardial infarction. Lessons to be learned.

Authors:  S Sherry
Journal:  Tex Heart Inst J       Date:  1991

Review 2.  ST segment changes as a surrogate end point in coronary thrombolysis.

Authors:  W S Hillis; K J Hogg
Journal:  Br Heart J       Date:  1990-08

3.  Rescue PTCA Following Failed Thrombolysis and Primary PTCA: A Retrospective Study of Angiographic and Clinical Outcome.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 4.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

5.  A study of coronary artery patency in relation to the index event in patients with myocardial infarction thrombolysed with streptokinase.

Authors:  R K Gokhroo; Sajal Gupta; Devendra Singh Bisht; Deepak Padmanabhan
Journal:  Heart Asia       Date:  2014-04-26

6.  Saruplase in Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

7.  Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.

Authors:  R Fears; H Ferres; E Glasgow; R Standring; K J Hogg; J D Gemmill; J M Burns; A P Rae; F G Dunn; W S Hillis
Journal:  Br Heart J       Date:  1992-08

Review 8.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

9.  Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.

Authors:  J D Gemmill; K J Hogg; F G Dunn; A P Rae; W S Hillis
Journal:  Br Heart J       Date:  1994-09

10.  Quality of life in the first 100 days after suspected acute myocardial infarction--a suitable trial endpoint?

Authors:  J Rawles; J Light; M Watt
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.